Evidence map›Paper›PMID 39868380›Full record

ArticleFrontiers in oncology2024

Survival analysis of recurrent ovarian cancer under different PARP inhibitor treatment patterns: a single-center retrospective study.

Jingtian Shen, Xi Wang, Olivier Mpano, Ying Wang, Yihan Shan, Xinning Lou, Piaopiao Ye, Xiaojian Yan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jingtian Shen *Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xi Wang *Department of Obstetrics and Gynecology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
Olivier MpanoDepartment of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ying WangDepartment of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yihan ShanDepartment of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xinning LouDepartment of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Piaopiao YeDepartment of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiaojian YanDepartment of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To compare the effects of different treatment modes containing PARPis and traditional treatment modes on the survival of patients with recurrent ovarian cancer. Methods: From December 2012 to December 2023, 131 recurrent ovarian cancer patients were screened. The patients were followed up retrospectively, and the relevant data was collected and analyzed. Results: Eighty-three patients used PARPis throughout the treatment process, and the median OS was not reached. Forty-eight patients did not use PARPis, and the median OS was 45.4 months. The two groups ' BRCA gene status, NACT, postoperative residual disease status, and PFI differ ( Conclusion: The use of PARPis, CA125 level and PFI were independent influencing factors of OS in patients with recurrent ovarian cancer. The first-line maintenance use of PARPis will not cause differences in disease recurrence characteristics. Compared with the patients without PARPis, patients with recurrent ovarian cancer receiving PARPis maintenance therapy have longer OS. The group of patients with PARPis maintenance treatment in the second and last lines showed better OS (

Indexed as

ovarian cancerPARP inhibitorsrecurrence characteristicsretrospective studysurvival analysis

Identifiers

PMID39868380
PMCPMC11757106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.